
MASH and Liver Disease Drug Development
MASH and Liver Disease Drug Development
Metabolic dysfunction-associated steatohepatitis and steatotic liver disease (MASH & MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease, affecting up to 30% of the world population. Its effects range from simple fat accumulation (steatosis) to inflammatorymediated fibrosis or cirrhosis – the most severe form of the disease called metabolic dysfunction-associated steatohepatitis (MASH). It is estimated that 20-25% of MASLD patients will advance to MASH during their lifetime, placing them at significantly increased risk for liver failure or liver cancer.
Our expert team integrates therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your MASLD/MASH study design, assuring high-quality data delivery and regulatory approval.
Scientific expertise
Our scientific experts include pathologists and scientific advisors in liver disease, infectious disease, translational genomics, and soluble protein biomarkers. We have participated in more than 25 hepatology studies in various capacities, and we provide custom product-specific assay support. Through collaboration with our parent organizations, we have a cross-company MASH and MASLD team with solid experience, global CRO expertise, and multiple reference testing services. This Center of Excellence (CoE) in MASH includes:
- experienced operations
- data management
- regulatory support
- medical teams
- a MASH network of proven investigators
Innovations in patient identification using proprietary algorithms and data resources assure the completion of a MASH clinical trial on time and within budget.
Experience
We offer an extensive test menu of liver function tests – both standard and custom tests - and the strategic guidance to address your study goals to ensure better outcomes and regulatory approvals.
Resource
MASH and Liver Disease Capabilities Factsheet
As a leading laboratory services organization for trials across the globe, we integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize your MASLD or MASH study design, assuring high-quality data delivery and regulatory approval.
Liver biopsy - the gold standard
Tissue biopsy diagnosis remains still the gold standard for the assessment of MASLD and MASH. The staging of the most critical component of MASH —fibrosis— is still best done at the microscope with the help of hematoxylin and eosin (H&E) and two special histochemical stains, Masson’s trichrome and a reticulin (silver) stain. Both stains are validated at our laboratories worldwide. Most patients in a clinical trial have an outside diagnosis and staging of MASH. Due to inter-observer variability, the archival tissues often need to be re-evaluated at the central lab to confirm that outside diagnosis. We have several liver-specialized pathologists who have reviewed tens of thousands of MASH cases over the last five years.
Non-invasive biomarkers for MASH
- We have several composite biomarker tests to evaluate for MASLD/MASH.
- Genetic factors may play an important role in determining the phenotypic manifestation and overall risk for NAFLD. We perform the testing for these genetic markers.
- We offer the Enhanced Liver Fibrosis (ELF™) Test, a blood test to assess the risk of MASLD/MASH progression and liver-related events by measuring three direct markers of fibrosis.
Global capabilities
Our global anatomic pathology services and central laboratory capabilities provide a streamlined operational management structure to ensure continuity and process alignment. We provide the following services to address your testing needs:
- state-of-the-art technologies
- quality management systems
- global capacity
- high-quality infrastructure
- project management
- sample processing
- long-term sample storage

Standard assays for liver function |
|
Liver Function/Test Method | Aspartate aminotransferase level (AST), Alanine aminotransferase level (AST), GGT, Apolipoprotein, Glucose levels, and Alkaline Phosphatase (ALP) |
Specialized Liver function tests |
Hyaluronic acid (HA), PIIINP, TIMP-1, Retinol binding protein-4 (RBP-4), Proc-3, GAL-3, YKL-40 |
Immunohistochemical Stains: CytoKeratin 18, Sonic HedgeHog (SHH) |
|
Histochemical Stains: Masson trichrome, Reticulin, Periodic acid-Schiff (with and without diastase), Prussian blue (iron), Orcein (copper), PicroSirius Red (PSR) |
|
Composite noninvasive biomarker tests |
Fibrosis-4 score (FIB4), MASLD Fibrosis score (NFS), Enhanced Liver Fibrosis (ELF) Score, Fibro test, NIS4 |
Genetic markers for NAFLD predisposition |
PNPLA3 - Single nucleotide polymorphism (SNP) |
TMS6SF2 - Single nucleotide polymorphism (SNP) |
|
Measurement of liver-specific miRNA levels |
miR-122, miR-34a |
Related Services

Central Laboratory Services
Learn more
Clinical Genomics Laboratory Services
Learn more